Header Logo

Connection

WALLIS MOLCHEN to Antiviral Agents

Back to Details
This is a "connection" page, showing publications WALLIS MOLCHEN has written about Antiviral Agents.
WALLIS MOLCHEN
Connection Strength
0.850
Antiviral Agents
  1. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011 Nov; 54(5):1527-37.
    View in: PubMed
    Score: 0.124
  2. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun; 140(7):1961-9.
    View in: PubMed
    Score: 0.118
  3. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 Mar-Apr; 51(2):137-48.
    View in: PubMed
    Score: 0.110
  4. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
    View in: PubMed
    Score: 0.101
  5. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405.
    View in: PubMed
    Score: 0.060
  6. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
    View in: PubMed
    Score: 0.059
  7. Automated summaries of serious adverse events in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Trials. 2009 Dec; 6(6):618-27.
    View in: PubMed
    Score: 0.054
  8. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37.
    View in: PubMed
    Score: 0.052
  9. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58.
    View in: PubMed
    Score: 0.052
  10. Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011 Dec; 21(12):851-60.
    View in: PubMed
    Score: 0.031
  11. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology. 2011 Jul; 141(1):141-9.
    View in: PubMed
    Score: 0.030
  12. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug; 54(2):434-42.
    View in: PubMed
    Score: 0.015
  13. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904.
    View in: PubMed
    Score: 0.015
  14. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140(5):1490-500.e3.
    View in: PubMed
    Score: 0.015
  15. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.